Focus: Passkey Therapeutics is a Cambridge-based biotechnology company with a portfolio spanning immunology, oncology, respiratory, neurology, and hematology, operating primarily through marketed generic and branded medications.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
No open roles listed right now. Follow Passkey Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generates 84% of company revenue but carries risk of continued erosion as a post-LOE generic with no exclusivity moat.
Help build intelligence for Passkey Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Passkey Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Small revenue contributor ($51K) facing patent expiration in December 2027, representing only $51K of $51K total at-risk revenue.
Post-LOE generic pain reliever generating $57K in Part D spending with no growth catalyst.
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo